Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based triple salvage therapy for Helicobacter pylori eradication
jRCTs031250216Recruiting
- Sponsor
- Yokohama City University
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in Helicobacter pylori infection comparing Vonoprazan + amoxicillin + rifabutin with Vonoprazan + amoxicillin + sitafloxacin (2 arms). Primary endpoint: Eradication rate. Started Feb 2026; status: recruiting.
02
Drugs
vonoprazanamoxicillinrifabutinsitafloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031250216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250216.